Sun Pharma vs Cipla (2026): Specialty Drugs, India, US Growth, Valuation & Which Is Better?
Sun Pharma and Cipla are both called generic pharmaceutical companies, but that description now misses the most important difference between them.
Sun Pharma has spent years building a global innovative-medicines business around specialty dermatology, oncology and other differentiated therapies. It is now attempting an even larger transformation through the proposed acquisition of Organon.
Cipla remains more anchored in branded pharmaceuticals, respiratory medicine, India, North America and selected global markets. Its strategy is increasingly complex too, but it is still a more focused company than Sun Pharma is becoming.
Sun Pharma currently has the stronger earnings engine
Sun Pharma's Q1 FY2027 revenue grew about 10.5% and reported profit increased approximately 27%, while Cipla's revenue rose only 2.3% and profit fell roughly 39%.
Those headline numbers need context.
Sun's reported PAT growth benefited partly from a lower exceptional-charge burden compared with the previous year. Adjusted profit growth was far lower than the reported 27% figure.
Cipla's profit decline came against an unusually strong North American base, where older high-value products had contributed substantially more in the previous year.
Even after allowing for those effects, Sun currently has the stronger earnings momentum.
Sun Pharma vs Cipla financial comparison
| Metric | Sun Pharma | Cipla | Current Edge |
|---|---|---|---|
| Market capitalisation | ₹468,821 Cr | ₹116,132 Cr | Sun Pharma |
| P/E | 38.76x | 34.45x | Cipla |
| P/B | 5.61x | 3.37x | Cipla |
| Industry P/E | 34.89x | 34.89x | Cipla near benchmark, Sun above it |
| ROE | 14.74% | 11.82% | Sun Pharma |
| ROCE | 19.31% | 15.67% | Sun Pharma |
| Net profit margin | 20.19% | 11.90% | Sun Pharma |
| 5-year sales growth | 11.78% | 8.01% | Sun Pharma |
| 5-year profit growth | 31.64% | 10.03% | Sun Pharma |
| 5-year EPS growth | 31.62% | 10.00% | Sun Pharma |
| 5-year free cash flow | ₹41,050 Cr | ₹13,262 Cr | Sun Pharma |
| Debt-to-equity | 0.05 | 0.01 | Cipla slightly |
| Interest coverage | 45.61x | 97.04x | Cipla |
| Current ratio | 2.82x | 3.44x | Cipla |
| Operating cash flow / PAT | 1.08x | 1.02x | Both healthy |
| Dividend yield | 0.82% | 0.90% | Cipla slightly |
| Promoter holding | 54.48% | 29.21% | Different ownership structures |
| Promoter pledge | 1.42% | 0% | Cipla |
| FII holding | 15.94% | 22.55% | Cipla |
| DII holding | 21.00% | 31.71% | Cipla |
| Bull Run Score | 66.4/100 | 40.2/100 | Sun Pharma |
Sun Pharma's Q1 growth came from India and innovative medicines
The quarter illustrates why Sun is no longer best understood as a conventional generics company.
Q1 FY2027 revenue from operations increased approximately 10.5% to about ₹15,300 crore.
Reported consolidated net profit attributable to owners increased roughly 27% to about ₹2,895 crore.
EBITDA increased approximately 3% to ₹4,418 crore.
EBITDA margin was around 28.9%, down from approximately 31.1% in the previous-year quarter.
India formulations sales increased 16% to approximately ₹5,475 crore.
Global innovative medicines sales increased about 12.9% to $351 million.
These two businesses offset weakness in US generics.
Sun's US business is changing from generics toward specialty
US formulations sales fell approximately 10% to $427 million in Q1 FY2027 despite growth in innovative medicines.
The pressure came from conventional generics, including reduced contribution from products such as lenalidomide.
This is important because Sun's US strategy increasingly depends on replacing commoditised generic revenue with differentiated therapies carrying stronger pricing power and longer commercial lives.
Products such as ILUMYA, LEQSELVI and UNLOXCYT illustrate that transition.
The business becomes more valuable if specialty growth offsets generic erosion consistently.
It becomes riskier if research spending rises faster than successful launches.
Cipla's Q1 problem was North America, not India
Cipla's consolidated Q1 revenue increased 2.3% to approximately ₹7,119 crore, but net profit fell about 39% to ₹789 crore.
The company attributed much of the profit pressure to a high previous-year base in North America and lower contribution from products such as generic Revlimid and lanreotide.
North American revenue fell materially.
The Indian business, by contrast, remained strong.
One India revenue reached approximately ₹3,452 crore, up around 12% year on year and representing its highest-ever quarterly revenue.
Respiratory, anti-diabetes and cardiac therapies remained important growth drivers.
Cipla's respiratory franchise is still its defining competitive advantage
Cipla has spent decades building deep expertise in inhalation and respiratory care across India and international markets.
Foracort crossed ₹1,000 crore of annual revenue in FY2026.
The company's North American strategy also increasingly relies on complex respiratory products rather than commodity tablets alone.
FY2026 North American revenue was approximately $780 million.
Cipla received approval for the first AB-rated generic Ventolin produced from its US facility.
Its longer-term US pipeline includes differentiated inhalation products such as generic Advair and Symbicort opportunities, subject to regulatory and commercial execution.
Sun Pharma's India business is substantially larger
Sun remains India's largest pharmaceutical company and reported approximately 8.5% domestic market share in Q1 FY2027 industry data cited by the company.
India formulations sales reached about ₹5,475 crore in the quarter.
Growth was led by chronic categories including cardiovascular, central nervous system, gastroenterology and orthopaedics.
The scale advantage matters because the Indian branded market can produce recurring prescriptions, strong brand equity and comparatively predictable pricing.
Cipla's One India business is also excellent, particularly in respiratory and chronic care, but its absolute sales base is smaller.
Cipla may have the cleaner balance sheet
Both companies currently carry very little conventional debt, but Cipla's liquidity ratios are stronger.
Cipla has debt-to-equity of approximately 0.01, a current ratio around 3.44x and interest coverage above 97x.
Sun Pharma's debt-to-equity is still low at about 0.05, with a current ratio around 2.82x and interest coverage of roughly 45.6x.
On the existing balance sheet alone, neither looks financially stretched.
That conclusion could change meaningfully for Sun if the proposed Organon transaction closes with substantial acquisition financing.
The Organon acquisition changes Sun Pharma's risk profile
Sun Pharma's proposed acquisition of Organon is large enough to reshape the company.
Sun agreed in April 2026 to acquire Organon in an all-cash transaction valuing the target at approximately $11.75 billion enterprise value.
Organon brings women's health, biosimilars and established pharmaceutical brands across multiple international markets.
The strategic logic is clear: more scale, broader geographic reach, additional specialty and women's-health exposure, and a more diversified global commercial platform.
The financial risk is equally clear.
A transaction of this size introduces financing, integration, execution and return-on-capital risk.
Sun Pharma's Q1 included roughly ₹167 crore of transaction-related Organon costs, with additional acquisition-related expenditure expected.
Organon shareholders approved the transaction in July 2026, but Sun and Organon continue to operate separately until closing.
Why the Organon deal could make today's Sun Pharma ratios temporary
The current 0.05 debt-to-equity ratio may not describe the post-acquisition balance sheet.
Large acquisitions can increase debt, interest expense, goodwill and intangible assets.
They can also temporarily reduce ROCE even when the strategic transaction ultimately creates value.
For Sun shareholders, one of the most important future metrics will therefore be not just revenue growth but incremental return on invested capital after Organon is consolidated.
The market may tolerate lower near-term ROCE if integration synergies and specialty growth are credible.
Cipla has no equivalent balance-sheet transformation underway
Cipla's strategy is more incremental.
The company is expanding through internal R&D, respiratory launches, biosimilar partnerships, metabolic-care partnerships and selected acquisitions rather than one transformational global deal of Organon's size.
That can reduce integration risk.
It may also limit how quickly Cipla can change its global scale.
Cipla's opportunity is to turn its strong India franchise and respiratory capabilities into a higher-quality international product mix without taking Sun Pharma-sized acquisition risk.
Sun has the much stronger five-year earnings record
Sun Pharma's five-year profit growth of approximately 31.6% is more than three times Cipla's roughly 10.0%.
Five-year EPS growth tells essentially the same story.
Sun's five-year sales growth is approximately 11.8%.
Cipla's is about 8.0%.
The combination of higher sales growth and much faster earnings growth suggests Sun has expanded margins and improved its business mix over the period.
The profitability gap is large
Sun Pharma's current net profit margin is approximately 20.2%, compared with Cipla around 11.9%.
Sun's ROE is about 14.7% versus Cipla around 11.8%.
ROCE is approximately 19.3% for Sun and 15.7% for Cipla.
These numbers help explain why Sun commands the higher valuation.
The question is whether those returns remain intact after a transformational acquisition.
Cipla is cheaper, but not dramatically cheap
Cipla trades at approximately 34.45x earnings, close to Bull Run's current pharma-industry P/E of around 34.89x.
Sun trades above the industry benchmark at roughly 38.76x.
Price-to-book shows a wider difference: approximately 3.37x for Cipla versus 5.61x for Sun.
Cipla therefore offers the lower starting valuation.
But the discount reflects slower current earnings growth and uncertainty around the North American earnings reset.
Sun's premium has a fundamental basis
Investors are paying more for Sun because the business currently generates higher margins, faster long-term earnings growth and a differentiated specialty pipeline.
The premium becomes vulnerable if innovative-medicine growth slows, US specialty launches disappoint or Organon integration destroys returns.
Conversely, successful integration could broaden the earnings base enough to make today's Sun Pharma look very different several years from now.
Cash flow is strong at both companies
Operating cash flow currently broadly supports accounting profit for both Sun and Cipla.
Sun's operating cash flow to net profit ratio is approximately 1.08x.
Cipla's is roughly 1.02x.
That is encouraging because pharmaceutical companies can carry substantial receivables, inventories and R&D expenditure.
Sun's five-year free cash flow is approximately ₹41,050 crore in Bull Run's current series.
Cipla's is about ₹13,262 crore.
Sun's larger cash-generation base becomes especially important if it needs to finance a major acquisition.
Dividend yield is not the main attraction of either stock
Cipla currently yields approximately 0.90% and Sun Pharma about 0.82%.
The difference is too small to drive a serious investment decision.
Both companies retain significant capital for R&D, product development, manufacturing, acquisitions and international expansion.
The more important shareholder-return question is how effectively retained earnings translate into future EPS and cash flow.
What has the stock market rewarded over the last year?
Sun Pharma has significantly outperformed Cipla.
| Market Metric | Sun Pharma | Cipla |
|---|---|---|
| Price on 25 Aug 2026 | ₹1,922 | ₹1,422 |
| 1-month return | -2.03% | +0.81% |
| 3-month return | +4.21% | +0.27% |
| 6-month return | +7.63% | +4.71% |
| 1-year return | +16.01% | -11.19% |
| 52-week high | ₹2,046.90 | ₹1,673 |
| 52-week low | ₹1,548 | ₹1,170 |
| RSI (14) | 36.53 | 26.76 |
Cipla's low RSI indicates weak recent price momentum, not automatically undervaluation.
Sun remains much closer to its 52-week high.
That relative performance reflects stronger earnings momentum and enthusiasm around the company's specialty strategy.
Promoter and institutional ownership differ substantially
Sun Pharma has higher promoter ownership; Cipla has heavier institutional ownership.
Sun promoter holding is approximately 54.48%, with around 1.42% of promoter holdings currently pledged in Bull Run's data.
Cipla promoter ownership is approximately 29.21% with zero promoter pledge.
FII holding is roughly 15.94% for Sun and 22.55% for Cipla.
DII ownership is approximately 21.0% for Sun and 31.71% for Cipla.
Institutional ownership alone is not a quality signal, but it provides useful context around market float and investor composition.
Sun Pharma: what the market is paying for
The strengths
- India's largest pharma franchise.
- 16% Q1 India formulations growth.
- Global innovative medicines growing double digits.
- 20.2% net profit margin.
- 31.6% five-year profit growth.
- 19.3% ROCE.
- Large free-cash-flow base.
- Specialty pipeline with global pricing power potential.
The risks
- Valuation above industry P/E.
- US generics remain under pressure.
- Specialty R&D is expensive and uncertain.
- Organon transaction is exceptionally large.
- Potential acquisition debt can change current balance-sheet quality.
- Integration risk may affect ROCE for years.
Cipla: what the market is paying for
The strengths
- Leading Indian respiratory franchise.
- Record Q1 One India revenue.
- Strong chronic-care brands.
- Very low conventional leverage.
- High interest coverage and liquidity.
- Complex US respiratory pipeline.
- Lower P/E and P/B than Sun Pharma.
- Large institutional ownership base.
The risks
- Q1 PAT fell sharply.
- North American revenue is resetting after high-value product decline.
- Lanreotide supply issues have affected the US portfolio.
- Upcoming launches must replace lost Revlimid contribution.
- ROE and ROCE trail Sun Pharma.
- Five-year earnings growth is substantially slower.
Sun Pharma vs Cipla: which wins each category?
Market scale: Sun Pharma.
Current P/E valuation: Cipla.
Current P/B valuation: Cipla.
ROE: Sun Pharma.
ROCE: Sun Pharma.
Net profit margin: Sun Pharma.
Five-year sales growth: Sun Pharma.
Five-year profit growth: Sun Pharma.
Five-year free cash flow: Sun Pharma.
Balance-sheet simplicity: Cipla currently.
India pharma scale: Sun Pharma.
Respiratory franchise: Cipla.
Global specialty medicines: Sun Pharma.
Current Q1 earnings momentum: Sun Pharma.
Current one-year market performance: Sun Pharma.
Bull Run Score: Sun Pharma.
Sun Pharma vs Cipla FAQs
Which company is bigger?
Sun Pharma, with a current market capitalisation of approximately ₹4.69 lakh crore versus Cipla around ₹1.16 lakh crore.
Which stock is cheaper?
Cipla on both P/E and P/B in Bull Run's current snapshot.
Which has better ROCE?
Sun Pharma, at approximately 19.3% compared with Cipla around 15.7%.
Which has better five-year profit growth?
Sun Pharma, at approximately 31.6% versus Cipla near 10.0%.
Which company is stronger in respiratory drugs?
Cipla has one of India's strongest respiratory franchises and a differentiated US inhalation pipeline.
Which is stronger in innovative specialty medicines?
Sun Pharma. Global innovative medicines have become an increasingly important part of its revenue and margin profile.
Why is Sun Pharma buying Organon?
The proposed deal would add global women's health, biosimilar and established-brand businesses and materially expand Sun Pharma's international commercial scale.
Which has the cleaner balance sheet today?
Cipla. Its current debt-to-equity is close to zero with very high interest coverage. Sun's current balance sheet is also strong, but the Organon transaction may change its leverage profile.
Research sources
- Bull Run current fundamentals, ownership and technical data
- Sun Pharma investor information and quarterly financials
- Sun Pharma FY2026 annual report
- Sun Pharma official Organon acquisition announcement
- Sun Pharma 2026 corporate disclosures
- Cipla official investor centre
- Cipla FY2026 annual report
- Cipla FY2026 investor presentation
Disclaimer
This article is for educational and informational purposes only. Pharmaceutical earnings can be affected by product exclusivity, regulatory approvals, inspections, litigation, pricing, R&D outcomes, acquisitions and foreign exchange. Sun Pharma's proposed Organon acquisition has not yet been reflected as a completed transaction in the current financial ratios used here. Financial metrics and market prices change over time. Nothing here recommends buying, selling or holding Sun Pharma, Cipla or any other security. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.